Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 2

WCLC Updates on the Emergence of ADCs in NSCLC

February 26, 2021

Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Sarah Goldberg, MD, MPH, Yale School of Medicine, Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Heather A. Wakelee, MD, Stanford University Medical Center

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC

Now Viewing

EP. 2: WCLC Updates on the Emergence of ADCs in NSCLC

EP. 3: WCLC Updates in Immunotherapy for NSCLC

EP. 4: WCLC Updates in Neoadjuvant Therapy for NSCLC

EP. 5: WCLC Updates in Locally Advanced NSCLC

EP. 6: WCLC Updates in Small Cell Lung Cancer

Data from the following clinical trials are discussed:

OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
OA03.04 - Efficacy and Safety of the Novel HER3-Directed Antibody-Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study